Prenetics Global Limited Class A Ordinary Share
PREPrenetics Global Limited is a leading healthtech company specializing in genetic testing, diagnostic services, and digital health solutions. Founded to advance personalized healthcare, the company offers a wide range of genetic and diagnostic testing services, including health and wellness insights, disease risk assessments, and COVID-19 testing. Through its innovative platform, Prenetics aims to empower individuals and healthcare providers with data-driven health information.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| March 1, 2016 | $0.70 | 2016-02-17 | 2016-02-19 |
| December 1, 2015 | $0.70 | 2015-11-04 | 2015-11-06 |
| September 1, 2015 | $0.70 | 2015-08-05 | 2015-08-07 |
| June 1, 2015 | $0.70 | 2015-05-06 | 2015-05-08 |
| February 27, 2015 | $0.70 | 2015-02-11 | 2015-02-13 |
Dividends Summary
- Consistent Payer: Prenetics Global Limited Class A Ordinary Share has rewarded shareholders with 50 dividend payments over the past 13 years.
- Total Returned Value: Investors who held PRE shares during this period received a total of $25.85 per share in dividend income.
- Latest Payout: The most recent dividend of $0.70/share was paid 3791 days ago, on March 1, 2016.
- Dividend Growth: Since 2003, the dividend payout has grown by 125.8%, from $0.31 to $0.70.
- Dividend Reliability: PRE has maintained or increased its dividend for 50 consecutive payments.
Company News
Prenetics Global Limited announced a $1 billion growth financing deal with General Catalyst's Customer Value Fund to accelerate IM8's marketing spend. The company raised its full-year 2026 revenue guidance to $210-220 million (from $190-210 million) and projects $300 million annualized run-rate by year-end 2026 and $400+ million in full-year 2027...
Prenetics Global Limited's IM8 brand has partnered with Superpower to create an integrated health platform combining clinical-grade supplements with comprehensive blood biomarker testing. IM8 90-day subscribers can access Superpower's annual blood testing membership for $49 (75% discount), while Superpower members gain access to IM8's Daily Ultim...
The global personalized nutrition market is projected to grow from $15.79 billion in 2025 to $30.94 billion by 2030 at a 14.4% CAGR. Digital tools and active measurement technologies are the fastest-growing segments, while Asia Pacific emerges as a high-growth regional hub driven by expanding middle class, rising lifestyle diseases, and rapid dig...
Prenetics Global Limited completed the sale of its 35% equity interest in Insighta to Tencent for $70 million in cash, bringing total adjusted liquidity to $171.1 million. The company operates with zero debt and plans to use the proceeds to accelerate IM8's global expansion. IM8, co-founded with David Beckham, has achieved over $100 million in an...
Prenetics Global Limited is launching a public offering of shares to fund global expansion of its IM8 health supplement brand and strategic Bitcoin accumulation, with plans to continue purchasing 1 Bitcoin daily.
